Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Hisamitsu One Step Closer to FY2019 Filing after NSAID Patch Delivers Positive PIII in Cancer Pain
Hisamitsu Pharmaceutical has delivered encouraging results from its re-designed Japan PIII trial on its investigational cancer pain drug HP-3150, setting the table for its planned filing within this fiscal year ending February 2020. The study looked into the efficacy and…
To read the full story
Related Article
- Hisamitsu Applies for Diclofenac Patch for Cancer Pain in Japan
February 28, 2020
- Hisamitsu Begins New Japan PIII for NSAIDs Patch after Unfavorable PII/III
July 20, 2017
- Hisamitsu’s NSAIDs Patch Disappoints in Japan PII/III
August 30, 2016
BUSINESS
- MSD Launches RSV Antibody Enflonsia in Japan without NHI Listing
August 24, 2026
- Sumitomo Pharma Eyes Global Position as Adjuvant Supplier
August 24, 2026
- Oncolys’ Oncolytic Virus Telomelysin Hits Japan Market
August 24, 2026
- Sobi’s Still’s Disease Drug Kineret Now Available in Japan
August 24, 2026
- MSD Files Welireg-Keytruda Combo in Japan for Adjuvant RCC
August 24, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…